Meeting
2016 ASCO Annual Meeting
Evaluation of cytomegalovirus (CMV) reactivation, relapse, and survival after allogeneic hematopoietic stem cell transplantation (allo-HSCT) using two T cell depletion strategies.
Authors
Talal Hilal
Markey Cancer Center, University of Kentucky, Lexington, KY
Talal Hilal , Shawn Peterson , Charles Bodine , Stacey A. Slone , Gerhard Hildebrandt , Zartash Gul
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Sub Track
Allogenic Stem Cell Transplantation
Citation
J Clin Oncol 34, 2016 (suppl; abstr 7047)
DOI
10.1200/JCO.2016.34.15_suppl.7047
Abstract #
7047
Poster Bd #
39
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Effect of disease status prior to T-cell depleted allogeneic stem cell transplantation on relapse-free and overall survival in patients with adverse-risk acute myeloid leukemia (AML).
First Author: Alexandra Ewa Rojek
Poster
2023 ASCO Annual Meeting
An analysis of a first-in-human study of NEXI-001 donor-derived antigen-specific CD8+ T-cell treatment of relapsed AML after allogeneic hematopoietic cell transplantation (HCT).
First Author: Monzr M. Al Malki
Poster
2022 ASCO Annual Meeting
Donor-derived T cells specific for tumor antigen and multiple pathogens for prevention of relapse and infection after haemopoietic stem cell transplant (HSCT) for myeloid malignancies (the INTACT trial).
First Author: Wei Jiang
Poster
2022 ASCO Annual Meeting
Phase I study of donor-derived CD5 CAR T cells in patients with relapsed or refractory T-cell acute lymphoblastic leukemia.
First Author: Jing Pan